Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Overview of the Japanese Pharma CRO Market 2019 - ResearchAndMarkets.com

May 22, 2019

DUBLIN--(BUSINESS WIRE)--May 22, 2019--

The “Overview of the Japanese CRO Market 2019” report has been added to ResearchAndMarkets.com’s offering.

This report takes an overview of the CRO market in Japan. By reading this report, readers will understand the overall picture of the Japanese CRO market, including the market size trends, major CRO players, in addition to the competitive differences between local and global CROs.

The Japanese CRO market has been expanding in recent years, and it reached over 180 Yen billion in 2017.

When the market is broken down by functional services, monitoring accounted for 58% of the total market and followed by data management with 14%.

Phase III occupies 42.2%, followed by PMS; post-marketing surveillance with 9.9%, and phase II with 9.2%.

There is still some room for pharma to outsource clinically related works. The rate of outsourcing will also increase a little in the coming years. Furthermore, the shortage of operational resources in pharma in the last 5 years enhanced the outsourcing works from pharma to CROs.

Japan may face a situation in which it loses some clinical trials to other regions, especially China in the near future. As trials shift to global studies from local ones, this tendency will increase over time.

Clients have introduced a preferred/strategic partnership model with top 6 CROs mentioned earlier, especially IQVIA. IQVIA had to turn down many of projects due to resource constraint in the last 5 years, and other CROs could reap the benefits, taking over those projects from IQVIA. The resource issue in CROs is now quickly resolving, as pharma is cutting many jobs and people are flowing into CROs. Due to better capability in global CROs, clients are shifting to selected global CROs, and this will increase over time.

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/r/toqczl

View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005419/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/22/2019 07:57 AM/DISC: 05/22/2019 07:57 AM


All contents © copyright 2019 The Associated Press. All rights reserved.